Guideline adherence and reasons for recommending dose reduction in a primary care-based opioid management clinic

Authors

DOI:

https://doi.org/10.5055/jom.2021.0682

Keywords:

opioid dose reduction, CDC guideline adherence, opioid management clinic, chronic pain, opioid tapering

Abstract

Background: To provide Centers for Disease Control and Prevention (CDC) guideline-recommended practices for patients on long-term opioid therapy (LTOT) including individualized decisions about opioid dose reduction, we developed the Power Over Pain (POP) Clinic.

Objective: To describe frequency and reasons for opioid dose reduction and pre–post adherence to CDC guideline-recommended practices.

Design: Retrospective chart review with qualitative and pre–post analysis.

Patients and setting: Patients at an urban internal medicine teaching practice-prescribed LTOT were seen at POP Clinic at least once.

Methods: Opioid dose reduction was defined by reduction in morphine-equivalent daily dose (MEDD) at 6 and 12 months after the first POP Clinic visit compared to baseline using paired t-tests. Among patients with a dose reduction, reasons documented in POP Clinic notes were qualitatively examined. Dichotomous measures of receiving four CDC guideline-recommended practices (controlled substance agreement [CSA], urine drug testing [UDT], prescription monitoring program review, and naloxone dispensing) at baseline versus 6 and 12 months were compared using McNemar's tests.

Results: Of the 70 patients, most were female (66 percent) and Hispanic (54 percent). Forty-three patients (61 percent) had an opioid dose reduction in 12 months after the first POP Clinic visit. The most frequent reason was low or unclear benefit of continuing the current dose (49 percent). Mean MEDD was reduced from 69 mg to 57 mg at 6 months (p < 0.01) and to 56 mg at 12 months (p < 0.01). Completing a CSA, UDT, and naloxone distribution increased at 6 and 12 months (p < 0.01).

Conclusions: Individualized risk assessment in a primary care-based opioid management clinic is feasible and can result in opioid dose reduction and guideline adherence.

 

Author Biographies

Laila Khalid, MD, MPH

Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York

Serena Roth, MD

Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York

Chenshu Zhang, PhD

Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York

Aaron Burkenroad, MD

University of California Los Angeles, Los Angeles, California

Gianni Carrozzi, MD

Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York

Joanna L. Starrels, MD, MS

Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York

References

Dowell D, Haegerich TM, Chou R: CDC guideline for prescribing opioids for chronic pain-United States, 2016. JAMA. 2016; 315(15): 1624-1645.

The Joint Commission: Joint Commission enhances pain assessment and management requirements for accredited hospitals. Off Newsl Jt Comm. 2017; 37(7): 2-4.

Rosenberg JM, Bilka BM, Wilson SM, et al.: Opioid therapy for chronic pain: Overview of the 2017 US department of veterans affairs and US department of defense clinical practice guideline. Pain Med. 2018; 19(5): 928-941.

Chou R, Fanciullo GJ, Fine PG, et al.: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10(2): 113-130.

Bohnert ASB, Valenstein M, Bair MJ, et al.: Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011; 305(13): 1315-1321.

Dunn KM, Saunders KW, Rutter CM, et al.: Opioid prescriptions for chronic pain and overdose: A cohort study. Ann Intern Med. 2010; 152(2): 85-92.

Gomes T, Mamdani MM, Dhalla IA, et al.: Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med. 2011; 171(7): 686-691.

Jamison RN, Sheehan KA, Scanlan E, et al.: Beliefs and attitudes about opioid prescribing and chronic pain management: Survey of primary care providers. J Opioid Manag. 2014; 10(6): 375-382.

Lange A, Lasser KE, Xuan Z, et al.: Variability in opioid prescription monitoring and evidence of aberrant medication taking behaviors in urban safety-net clinics. Pain. 2015; 156(2): 335-340.

Harle CA, Bauer SE, Hoang HQ, et al.: Decision support for chronic pain care: How do primary care physicians decide when to prescribe opioids? A qualitative study. BMC Fam Pract. 2015; 16(1): 1-8.

Krebs EE, Bergman AA, Coffing JM, et al.: Barriers to guideline- concordant opioid management in primary care—A qualitative study. J Pain. 2014; 15(11): 1148-1155.

Huffman KL, Rush TE, Fan Y, et al.: Sustained improvements in pain, mood, function and opioid use post interdisciplinary pain rehabilitation in patients weaned from high and low dose chronic opioid therapy. Pain. 2017; 158(7): 1380-1394.

Murphy JL, Clark ME, Banou E: Opioid cessation and multidimensional outcomes after interdisciplinary chronic pain treatment. Clin J Pain. 2013; 29(2): 109-117.

Khalid L, Liebschutz JM, Xuan Z, et al.: Adherence to prescription opioid monitoring guidelines among residents and attending physicians in the primary care setting. Pain Med. 2015; 16(3): 480-487.

Gupta R, Dube K, Bodenheimer T: The road to excellence for primary care resident teaching clinics. Acad Med. 2016; 91(4): 458-461.

Walker KO, Calmes D, Hanna N: The impact of public hospital closure on medical and residency education: Implications and recommendations. J Natl Med Assoc. 2008; 100(12): 1377-1383.

Chatterjee P, Joynt KE, Orav EJ, et al.: Patient experience in safety-net hospitals: Implications for improving care and value-based purchasing. Arch Intern Med. 2012; 172(16): 1204-1210.

Sullivan MD, Turner JA, DiLodovico C, et al.: Prescription opioid taper support for outpatient with chronic pain: A randomized controlled trial. J Pain. 2017; 18(3): 308-318.

Liebschutz JM, Xuan Z, Shanahan CW, et al.: Improving adherence to long-term opioid therapy guidelines to reduce opioid misuse in primary care: A cluster-randomized clinical trial. JAMA Intern Med. 2017; 177(9): 1265-1272.

Quanbeck A, Brown RT, Zgierska AE, et al.: A randomized matched-pairs study of feasibility, acceptability, and effectiveness of systems consultation: A novel implementation strategy for adopting clinical guidelines for opioid prescribing in primary care. Implement Sci. 2018; 13(1): 1-13.

Seal K, Becker W, Tighe J, et al.: Managing chronic pain in primary care: It really does take a village. J Gen Intern Med. 2017; 32(8): 931-934.

Westanmo A, Marshall P, Jones E, et al.: Opioid dose reduction in a VA health care system-implementation of a primary care population-level initiative. Pain Med. 2015; 16(5): 1019-1026.

US Department of Health and Human Services. HHS Guide for Clinicians on the Appropriate Dosage Reduction or Discontinuation of Long-Term Opioid Analgesics. Available at https://www.hhs.gov/opioids/treatment/clinicians-guide-opioiddosage-reduction/index.html. Accessed January 18, 2021.

Lovejoy TI, Morasco BJ, Demidenko MI, et al.: Reasons for discontinuation of long-term opioid therapy in patients with and without substance use disorders. Pain. 2017; 158(3): 526-534.

Husain JM, LaRochelle M, Keosaian J, et al.: Reasons for opioid discontinuation and unintended consequences following opioid discontinuation within the TOPCARE trial. Pain Med. 2019; 20(7): 1330-1337.

Dowell D, Haegerich T, Chou R: No shortcuts to safer opioid prescribing. N Engl J Med. 2019; 380(24): 2285-2287.

Starrels JL, Becker WC, Weiner MG, et al.: Low use of opioid risk reduction strategies in primary care even for high risk patients with chronic pain. J Gen Intern Med. 2011; 26(9): 958-964.

Huang KTL, Blazey-Martin D, Chandler D, et al.: A multicomponent intervention to improve adherence to opioid prescribing and monitoring guidelines in primary care. J Opioid Manag. 2019; 15(6): 445-453.

Coffin PO, Behar E, Rowe C, et al.: Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. Ann Intern Med. 2016; 165(4): 245-252.

Cariveau D, Fay AE, Baker D, et al.: Evaluation of a pharmacist-led naloxone coprescribing program in primary care. J Am Pharm Assoc. 2019; 59(6): 867-871.

Binswanger IA, Joseph N, Hanratty R, et al.: Novel opioid safety clinic initiative to deliver guideline-concordant chronic opioid therapy in primary care. Mayo Clin Proc Innov Qual Outcomes. 2018; 2(4): 309-316.

Takeda MY, Katzman JG, Dole E, et al.: Co-prescription of naloxone as a universal precautions model for patients on chronic opioid therapy-observational study. Subst Abus. 2016; 37(4): 591-596.

Spelman JF, Peglow S, Schwartz AR,et al.: Group visits for overdose education and naloxone distribution in primary care: A pilot quality improvement initiative. Pain Med. 2017;18(12): 2325-2330.

Frank JW, Levy C, Matlock DD, et al.: Patients’ perspectives on tapering of chronic opioid therapy: A qualitative study. Pain Med. 2016; 17(10): 1838-1847.

Published

11/01/2021

How to Cite

Khalid, MD, MPH, L., S. Roth, MD, C. Zhang, PhD, A. Burkenroad, MD, G. Carrozzi, MD, and J. L. Starrels, MD, MS. “Guideline Adherence and Reasons for Recommending Dose Reduction in a Primary Care-Based Opioid Management Clinic”. Journal of Opioid Management, vol. 17, no. 6, Nov. 2021, pp. 481-8, doi:10.5055/jom.2021.0682.